Myricx Bio is developing small molecule inhibitors of cMyc, a protein that is deregulated in over 70% of all human cancers. The company has strategic partnerships with Australia’s leading integrated cancer centre, the Peter MacCallum Cancer Centre, and Australia’s premier government research organisation, CSIRO.
Myricx Bio is based in Melbourne, Australia and conducts its research and discovery activities through service providers and research collaborators in Europe, UK, USA and Australia.
https://myricxbio.com/
Myricx Bio is based in Melbourne, Australia and conducts its research and discovery activities through service providers and research collaborators in Europe, UK, USA and Australia.
https://myricxbio.com/
Total raised: $115.69M
Investors 1
| Date | Name | Website |
| 07.11.2023 | Brandon Ca... | brandoncap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.07.2024 | Series A | $115.69M | - |
Mentions in press and media 7
| Date | Title | Description |
| 12.07.2024 | Myricx Bio: Revolutionizing Cancer Treatment with Novel Payloads | Myricx Bio, a UK-based biotech company, has secured a whopping £90 million in Series A funding to develop a groundbreaking class of payloads for antibody-drug conjugates (ADCs). Led by Novo Holdings and Abingworth, this investment marks a s... |
| 11.07.2024 | Myricx Bio Raises £90 Million In Series A To Develop Pay Class For Antibody-Drug Conjugates | Life science investor Novo Holdings announced that it has co-led a £90 million ($114 million) Series A financing for Myricx Bio, the largest European biotech Series A funding this year. Myricx Bio is a UK biotech company focusing on the dis... |
| 08.07.2024 | Myricx Bio Raises £90M in Series A Funding | Myricx Bio, a London, UK-based biotech company focusing on the discovery and development of a novel payload class for antibody-drug conjugates (ADCs), raised £90M ($114M) in Series A funding. The round was led by Novo Holdings and Abingwort... |
| 27.11.2023 | Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies | Scientists Uncover Central Role of N-Myristoylation in Senescence |
| 15.11.2023 | Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors | London, UK 15 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), toda... |
| 19.10.2023 | Myricx Bio Wins Best Poster at World ADC | London, UK, 19 October 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has won the awar... |
| - | Myricx Bio | “Myricx Bio – Developing the first class of ADCs based on NMT inhibition to treat cancer” |